Literature DB >> 8536794

Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates.

A F Laurent1, S Dumont, P Poindron, C D Muller.   

Abstract

Mycophenolic acid (MPA) is the active part of the corresponding morpholinoethyl ester pro-drug Mycophenolate Mofetil. MPA, an inhibitor of IMP dehydrogenase, depletes GTP and thereby suppresses transfer of mannose and fucose to proteins. Treatment of human monocytes with a clinically attainable concentration of MPA (10 microM) decreases their attachment to endothelial cells and to laminin, but not to type I collagen or fibronectin. Our results not only elucidate a major role of mannose/fucose residues in homing of monocytes on activated endothelium but also explain in part the beneficial effects of MPA in rheumatoid arthritis and organ graft rejection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8536794

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  18 in total

1.  Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil.

Authors:  Asha Moudgil; Ronald M Przygodzki; Kanwal K Kher
Journal:  Pediatr Nephrol       Date:  2005-12-17       Impact factor: 3.714

2.  Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency.

Authors:  P Högger; U Erpenstein; P Rohdewald; C Sorg
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

3.  Pulmonary alveolar proteinosis in a 67-year-old woman with Wegener's granulomatosis.

Authors:  Shiwan K Shah; Nghi B Phan; Geetinder Goyal; Gulshan Sharma
Journal:  J Gen Intern Med       Date:  2010-07-10       Impact factor: 5.128

4.  Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years.

Authors:  Adnan N Kiani; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2011-07-27       Impact factor: 2.631

5.  Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.

Authors:  Jodi L Karnell; Fredrick G Karnell; Geoffrey L Stephens; Bhargavi Rajan; Chris Morehouse; Ying Li; Bonnie Swerdlow; Mildred Wilson; Raphaela Goldbach-Mansky; Christopher Groves; Anthony J Coyle; Ronald Herbst; Rachel Ettinger
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

Review 6.  Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.

Authors:  Asha Moudgil; Arvind Bagga; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

7.  Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.

Authors:  D Maksimovic-Ivanic; V Trajkovic; D J Miljkovic; M Mostarica Stojkovic; S Stosic-Grujicic
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells.

Authors:  M Colic; Z Stojic-Vukanic; B Pavlovic; D Jandric; I Stefanoska
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

9.  Brain dead donor kidneys are immunologically active: is intervention justified?

Authors:  G Vergoulas; P Boura; G Efstathiadis
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

10.  EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil.

Authors:  Brian Patrick O'Neill; Steven Vernino; Ahmet Dogan; Caterina Giannini
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.